{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T02:14:24Z","timestamp":1784945664316,"version":"3.55.0"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Addition of spironolactone (SPR) to angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) might provide antiproteinuric effects beyond what is gained by either medication alone. This study was designed to assess the long-term efficacy of SPR\/ARB combination in comparison with the standard ACE\/ARB regimen in diabetic nephropathy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In an open-label, parallel-group, single-center, randomized clinical trial (NCT01667614), 136 patients with diabetes and proteinuria, already treated with enalapril and losartan, were included. In 74 patients, ACE inhibitors were discontinued. After a wash-out period of 2 weeks, 25 mg SPR daily was initiated. The remainder of the patients (n = 62) received ACE inhibitors and ARBs as before. Patients were followed every 3 months for 18 months. During each visit, systolic and diastolic blood pressure (BP), urinary albumin excretion (UAE), serum creatinine, estimated glomerular filtration rate (eGFR) and serum potassium concentrations were determined.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>After 18 months, three patients in the SPR\/ARB group developed asymptomatic hyperkalemia. SPR\/ARB significantly reduced both systolic and diastolic BP (P &amp;lt; 0.001 and 0.001, respectively). SPR\/ARB decreased UAE by 46, 72 and 59% after 3, 12 and 18 months, respectively. Compared with the continuation regimen, SPR\/ARB was superior in UAE reduction (P = 0.017 after 18 months), independent of BP change. In both groups, eGFR declined significantly over the trial course and the decline rate did not differ significantly between the two groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Addition of SPR to ARB provides added benefits with respect to BP control and proteinuria diminution. These antiproteinuric effects are not accompanied by prevention of eGFR loss compared with conventional therapy with ACE\/ARB.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ndt\/gft281","type":"journal-article","created":{"date-parts":[[2013,9,6]],"date-time":"2013-09-06T01:09:53Z","timestamp":1378429793000},"page":"2823-2833","source":"Crossref","is-referenced-by-count":51,"title":["Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial"],"prefix":"10.1093","volume":"28","author":[{"given":"Alireza","family":"Esteghamati","sequence":"first","affiliation":[{"name":"Endocrinology and Metabolism Research Center (EMRC), Vali-Asr Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina","family":"Noshad","sequence":"first","affiliation":[{"name":"Endocrinology and Metabolism Research Center (EMRC), Vali-Asr Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sorour","family":"Jarrah","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy, Department of Clinical Pharmacy, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa","family":"Mousavizadeh","sequence":"first","affiliation":[{"name":"Endocrinology and Metabolism Research Center (EMRC), Vali-Asr Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Hamid","family":"Khoee","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy, Department of Clinical Pharmacy, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manouchehr","family":"Nakhjavani","sequence":"first","affiliation":[{"name":"Endocrinology and Metabolism Research Center (EMRC), Vali-Asr Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2013,9,5]]},"reference":[{"key":"2020070208035785600_GFT281C1","doi-asserted-by":"crossref","first-page":"476","DOI":"10.2337\/diacare.25.3.476","article-title":"Lifetime costs of complications resulting from type 2 diabetes in the U.S","volume":"25","author":"Caro","year":"2002","journal-title":"Diabetes Care"},{"key":"2020070208035785600_GFT281C2","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1001\/archinte.159.16.1873","article-title":"The progressive cost of complications in type 2 diabetes mellitus","volume":"159","author":"Brown","year":"1999","journal-title":"Arch Intern Med"},{"key":"2020070208035785600_GFT281C3","doi-asserted-by":"crossref","first-page":"e26864","DOI":"10.1371\/journal.pone.0026864","article-title":"Cost-of-illness analysis of type 2 diabetes mellitus in Iran","volume":"6","author":"Javanbakht","year":"2011","journal-title":"PLoS One"},{"key":"2020070208035785600_GFT281C4","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.2337\/db05-1620","article-title":"Risk factors for renal dysfunction in type 2 diabetes","volume":"55","author":"Retnakaran","year":"2006","journal-title":"Diabetes"},{"issue":"Suppl 1","key":"2020070208035785600_GFT281C5","first-page":"S11","article-title":"Standards of medical care in diabetes\u20142012","volume":"35","author":"American Diabetes Association","year":"2012","journal-title":"Diabetes Care"},{"key":"2020070208035785600_GFT281C6","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"2020070208035785600_GFT281C7","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1053\/j.ajkd.2006.10.014","article-title":"Antihypertensive therapy in the presence of proteinuria","volume":"49","author":"Sarafidis","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"2020070208035785600_GFT281C8","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(98)10363-X","article-title":"Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria","volume":"354","author":"Ruggenenti","year":"1999","journal-title":"Lancet"},{"key":"2020070208035785600_GFT281C9","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"key":"2020070208035785600_GFT281C10","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.2215\/CJN.01410210","article-title":"Aldosterone: role in edematous disorders, hypertension, chronic renal failure, and metabolic syndrome","volume":"5","author":"Schrier","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"2020070208035785600_GFT281C11","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1111\/j.1523-1755.2005.00756.x","article-title":"Beneficial impact of spironolactone in diabetic nephropathy","volume":"68","author":"Schjoedt","year":"2005","journal-title":"Kidney Int"},{"key":"2020070208035785600_GFT281C12","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/ki.2011.48","article-title":"Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease","volume":"79","author":"Bertocchio","year":"2011","journal-title":"Kidney Int"},{"key":"2020070208035785600_GFT281C13","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1038\/sj.ki.5001854","article-title":"Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease","volume":"70","author":"Bianchi","year":"2006","journal-title":"Kidney Int"},{"key":"2020070208035785600_GFT281C14","doi-asserted-by":"crossref","first-page":"e184","DOI":"10.1111\/j.1464-5491.2012.03585.x","article-title":"Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study","volume":"29","author":"Nielsen","year":"2012","journal-title":"Diabet Med"},{"key":"2020070208035785600_GFT281C15","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.2337\/diacare.28.9.2106","article-title":"Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study","volume":"28","author":"Rossing","year":"2005","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"2020070208035785600_GFT281C16","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.2337\/dc12-s064","article-title":"Diagnosis and classification of diabetes mellitus","volume":"35","author":"American Diabetes Association","year":"2012","journal-title":"Diabetes Care"},{"key":"2020070208035785600_GFT281C17","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2020070208035785600_GFT281C18","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1056\/NEJM200109203451215","article-title":"Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease","volume":"345","author":"Chrysostomou","year":"2001","journal-title":"N Engl J Med"},{"key":"2020070208035785600_GFT281C19","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.amjhyper.2004.06.029","article-title":"Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease","volume":"18","author":"Sato","year":"2005","journal-title":"Am J Hypertens"},{"key":"2020070208035785600_GFT281C20","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1053\/j.ajkd.2007.10.040","article-title":"Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review","volume":"51","author":"Bomback","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"2020070208035785600_GFT281C21","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1681\/ASN.2009070737","article-title":"Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy","volume":"20","author":"Mehdi","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"2020070208035785600_GFT281C22","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/sj.ki.5001580","article-title":"Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy","volume":"70","author":"Schjoedt","year":"2006","journal-title":"Kidney Int"},{"key":"2020070208035785600_GFT281C23","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1097\/01.hjh.0000249708.44016.5c","article-title":"Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function","volume":"24","author":"van den Meiracker","year":"2006","journal-title":"J Hypertens"},{"key":"2020070208035785600_GFT281C24","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2215\/CJN.00240106","article-title":"Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes","volume":"1","author":"Epstein","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"2020070208035785600_GFT281C25","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1053\/j.ajkd.2005.03.007","article-title":"Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study","volume":"46","author":"Bianchi","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"2020070208035785600_GFT281C26","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1159\/000237742","article-title":"Predictors of hyperkalemia risk following hypertension control with aldosterone blockade","volume":"30","author":"Khosla","year":"2009","journal-title":"Am J Nephrol"},{"key":"2020070208035785600_GFT281C27","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"2020070208035785600_GFT281C28","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"key":"2020070208035785600_GFT281C29","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1136\/bmj.327.7407.147","article-title":"Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases","volume":"327","author":"Wrenger","year":"2003","journal-title":"BMJ"},{"key":"2020070208035785600_GFT281C30","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2020070208035785600_GFT281C31","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2215\/CJN.01040905","article-title":"Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker","volume":"1","author":"Chrysostomou","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"2020070208035785600_GFT281C32","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.amjhyper.2007.09.001","article-title":"Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus","volume":"20","author":"Yoneda","year":"2007","journal-title":"Am J Hypertens"},{"key":"2020070208035785600_GFT281C33","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1161\/01.HYP.0000044937.95080.E9","article-title":"Effectiveness of aldosterone blockade in patients with diabetic nephropathy","volume":"41","author":"Sato","year":"2003","journal-title":"Hypertension"},{"key":"2020070208035785600_GFT281C34","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1159\/000077396","article-title":"Aldosterone antagonism ameliorates proteinuria and nephrosclerosis independent of glomerular dynamics in L-NAME\/SHR model","volume":"24","author":"Zhou","year":"2004","journal-title":"Am J Nephrol"},{"key":"2020070208035785600_GFT281C35","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s10157-008-0034-9","article-title":"Aldosterone and glomerular podocyte injury","volume":"12","author":"Nagase","year":"2008","journal-title":"Clin Exp Nephrol"},{"key":"2020070208035785600_GFT281C36","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1161\/01.HYP.0000255636.11931.a2","article-title":"Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1","volume":"49","author":"Shibata","year":"2007","journal-title":"Hypertension"},{"key":"2020070208035785600_GFT281C37","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nm1545","article-title":"Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity","volume":"13","author":"Leopold","year":"2007","journal-title":"Nat Med"},{"key":"2020070208035785600_GFT281C38","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.mce.2009.02.005","article-title":"New aspects of rapid aldosterone signaling","volume":"308","author":"Grossmann","year":"2009","journal-title":"Mol Cell Endocrinol"},{"key":"2020070208035785600_GFT281C39","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/s11906-010-0126-2","article-title":"Mineralocorticoid receptor antagonists and the metabolic syndrome","volume":"12","author":"Tirosh","year":"2010","journal-title":"Curr Hypertens Rep"},{"key":"2020070208035785600_GFT281C40","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1681\/ASN.2008121270","article-title":"Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes","volume":"20","author":"Ninomiya","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"Suppl 2","key":"2020070208035785600_GFT281C41","first-page":"B54","article-title":"Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes","volume":"23","author":"Estacio","year":"2000","journal-title":"Diabetes Care"},{"key":"2020070208035785600_GFT281C42","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(98)07368-1","article-title":"Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study","volume":"353","author":"Gaede","year":"1999","journal-title":"Lancet"},{"key":"2020070208035785600_GFT281C43","first-page":"S150","article-title":"Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria","volume":"45","author":"Lebovitz","year":"1994","journal-title":"Kidney Int Suppl"},{"key":"2020070208035785600_GFT281C44","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1046\/j.1523-1755.2000.00879.x","article-title":"Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients","volume":"57","author":"Chan","year":"2000","journal-title":"Kidney Int"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/28\/11\/2823\/33456646\/gft281.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/28\/11\/2823\/33456646\/gft281.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T12:04:15Z","timestamp":1593691455000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/28\/11\/2823\/1823119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,5]]},"references-count":44,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2013,9,5]]},"published-print":{"date-parts":[[2013,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gft281","relation":{},"ISSN":["1460-2385","0931-0509"],"issn-type":[{"value":"1460-2385","type":"electronic"},{"value":"0931-0509","type":"print"}],"subject":[],"published-other":{"date-parts":[[2013,11]]},"published":{"date-parts":[[2013,9,5]]}}}